The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
The product will be marketed by Dr. Reddy's
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
Asthma patients are more likely to have an asthma attack during winter
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
Flattish volume growth and subdued new launches were key factors for last month
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Subscribe To Our Newsletter & Stay Updated
